ClinicalTrials.gg
RecruitingNCT07390903Updated Feb 5, 2026

GLS in Difficult CPB Weaning

An observational study in Cardiopulmonary Bypass, Coronary Artery Bypass and Heart Valve Diseases, sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital. Recruiting at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
213
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 48 studies in Heart Valve Diseases with a site in Italy — 21 open to participants now, 26 under way, none of them phase 3. Heart Valve Diseases · Italy.

Planned enrollment
14th of 28
213 · median 207
Started
2026
with 1 other
Observational
28 of 48
15 open now
Primary completion
2026-07
later than 11 of 25 live
Registered
48th of 48
by date

Among the 48 studies in Heart Valve Diseases with a site in Italy, this one is the 14th largest by planned enrollment of the 28 observational ones that give a count, is one of 2 that started in 2026, is one of 28 observational ones, reaches primary completion later than 11 of the 25 other live ones, and was the 48th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

21 of the 48 studies in Heart Valve Diseases with a site in Italy are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Heart Valve Diseases with a site in Italy, or all of them as a file.
02

Study summary

The goal of this observational study is to learn whether global longitudinal strain (GLS), measured by echocardiography, can predict difficulty separating from cardiopulmonary bypass (CPB) in adults undergoing elective cardiac surgery.

The main questions it aims to answer are:

  • Can preoperative GLS measurement predict difficult separation from CPB?
  • Are GLS values associated with outcomes such as intensive care unit (ICU) stay, hospital stay, cardiac biomarkers, or 30-day mortality?

Participants will:

  • Undergo standard cardiac surgery requiring CPB
  • Have echocardiographic assessments (TTE before and after surgery)
  • Have their recovery and outcomes monitored, including ICU and hospital stay, postoperative labs, and survival within 30 days
Read the detailed description

Background and Rationale

Difficult separation from cardiopulmonary bypass (CPB) is a serious intraoperative complication associated with increased perioperative morbidity and mortality. Myocardial contractility is the key determinant of successful CPB separation, and perioperative echocardiography is an established method for evaluating ventricular function. Conventionally, left ventricular ejection fraction (LVEF) measured by Simpson's biplane method is used to assess myocardial performance. However, LVEF has notable limitations, including high inter-operator variability, preload/afterload dependence, and poor sensitivity in detecting early myocardial dysfunction.

Global longitudinal strain (GLS), measured by two-dimensional speckle-tracking echocardiography, has emerged as a sensitive, reproducible, and geometry-independent parameter of myocardial function. GLS can detect subtle ventricular dysfunction earlier than conventional LVEF and has demonstrated prognostic value in a variety of clinical settings. Despite this, its use in the perioperative cardiac surgery population remains limited, partly due to uncertainty about the optimal timing of assessment. Anesthesia induction, CPB, and myocardial protection strategies may alter myocardial performance, and therefore both absolute GLS values and dynamic perioperative changes may carry prognostic significance.

Study Objectives

The primary objective of this prospective, multicenter, observational study is to evaluate the predictive value of GLS measurements for difficult separation from CPB. Specifically, the study will assess whether GLS measured by preoperative transthoracic echocardiography (TTE) can independently predict the need for multiple inotropic/vasoactive agents during CPB weaning.

Secondary objectives include exploring the associations between GLS parameters and postoperative outcomes such as intensive care unit (ICU) and hospital length of stay, postoperative changes in cardiac biomarkers, and all-cause 30-day mortality.

Methods

Eligible patients are adults (>18 years) scheduled for elective cardiac surgery requiring CPB, including isolated valve replacement or repair, coronary artery bypass grafting (CABG), combined procedures, and ascending aortic/arch surgery. Patients undergoing emergency or redo surgery, those with contraindications to TEE, or in critical preoperative states (mechanical circulatory support, inotrope dependence, atrial fibrillation, or mechanical ventilation) are excluded.

Echocardiographic assessments are performed at standardized time points: preoperative TTE (T1), intraoperative TEE after induction (T2, if performed), before CPB initiation (T3), immediately after CPB weaning (T4), and following sternal closure (T5). Intraoperative TEE is not mandated by the protocol but may be performed according to institutional practice or operator discretion. GLS analysis follows American Society of Echocardiography (ASE) guidelines, averaging strain from 18 myocardial segments.

Anesthetic and surgical protocols follow institutional standards, with cardioplegia delivered via Buckberg's or del Nido solutions. Clinical, intraoperative, and postoperative data-including operative times, need for pharmacologic support, and recovery variables-are collected systematically by trained staff.

Outcomes

  • Primary Endpoint: Ability of GLS value to predict difficult CPB separation, defined as the need for at least two vasoactive or inotropic agents.
  • Secondary Endpoints: Association of GLS with ICU/hospital length of stay, postoperative biomarker trends, hospital readmission, and all-cause mortality within 30 days.

Significance

This study addresses a clinically important knowledge gap by evaluating the GLS as a novel predictor of intraoperative difficulty and adverse outcomes in cardiac surgery. If validated, GLS assessment could enhance perioperative risk stratification, guide intraoperative decision-making, and ultimately improve patient outcomes.

03

Conditions studied

  • Cardiopulmonary Bypass
  • Coronary Artery Bypass
  • Heart Valve Diseases
  • Echocardiography
  • Intraoperative Complications
  • Postoperative Complications (Cardiopulmonary)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients scheduled for elective cardiac surgery requiring cardiopulmonary bypass at participating tertiary cardiac surgery centers. The study recruits participants from routine surgical practice in academic and high-volume referral hospitals, where both valve and coronary artery procedures are performed. Consecutive eligible patients who provide informed consent are enrolled prospectively.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years.
  • Scheduled for elective cardiac surgery requiring cardiopulmonary bypass (CPB).
  • Provided written to participate.
  • Eligible surgical procedures include:

    • Isolated mitral valve replacement or repair.
    • Isolated aortic valve replacement or repair.
    • Isolated coronary artery bypass grafting (CABG).
    • Combined valve and CABG surgery.
    • Multiple valve replacement or repair.
    • Surgery involving the ascending aorta or aortic arch.

Exclusion criteria

Exclusion Criteria

  • Emergency cardiac surgery.
  • Redo cardiac surgery.
  • to transesophageal echocardiography (TEE).
  • Critical preoperative conditions, including:

    • Ongoing inotropic drug therapy.
    • Preoperative mechanical circulatory support (e.g., IABP, ECMO, VAD).
    • Requirement for mechanical ventilation.
    • Preoperative atrial fibrillation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
213 participants (estimated)
Patient registry
No

Groups and cohorts

  • Easy CPB Separation

    Easy separation from CPB was defined as no pharmacologic support or use of a single agent (either vasoactive or inotropic).

    Diagnostic Test: Myocardial strain imaging

  • Difficult CPB Separation

    Difficult CPB separation can be defined as the need of at least 2 inotropes or vasopressors to successfully accomplish the separation from CPB.

    Diagnostic Test: Myocardial strain imaging

Interventions

  • Diagnostic testMyocardial strain imaging

    Two-dimensional strain analysis was performed using frame-by-frame tracking of unique patterns of bright and dark pixels in grayscale (B-mode) sector images to assess myocardial deformation. The frame rate was maintained between 40 and 90 Hz. The myocardium in each image was divided into six myocardial segments, which were individually assessed for tracking quality. GLS was calculated as the average strain value of 18 myocardial segments obtained from the three echocardiographic views. Patients were included in the final analysis if at least 15 out of 18 segments were considered acceptable for strain measurement by the investigator.

06

What researchers measure

Primary outcomes

  1. To evaluate the predictive value of GLS measurements for difficult separation from cardiopulmonary bypass.

    Separating from CPB was categorized as easy and difficult separation from CPB. Easy separation from CPB was defined as no pharmacologic support or use of a single agent (either vasoactive or inotropic). Difficult CPB separation can be defined as the need of at least 2 inotropes or vasopressors to successfully accomplish the separation from CPB

    Time frame: perioperative

Secondary outcomes

  1. To assess the associations between strain imaging and ICU/hospital length of stay, postoperative trajectories of cardiac biomarkers, and all-cause mortality.

    Time frame: Post operative 30 days

07

Study locations

2 of 2 sites recruiting
  • University of Rome Tor Vergata
    Rome, Italy
    Recruiting
  • Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
    Istanbul, Turkey (Türkiye)
    Recruiting
08

References and documents

Publications

  • Monaco F, Di Prima AL, Kim JH, Plamondon MJ, Yavorovskiy A, Likhvantsev V, Lomivorotov V, Hajjar LA, Landoni G, Riha H, Farag AMGA, Gazivoda G, Silva FS, Lei C, Bradic N, El-Tahan MR, Bukamal NAR, Sun L, Wang CY. Management of Challenging Cardiopulmonary Bypass Separation. J Cardiothorac Vasc Anesth. 2020 Jun;34(6):1622-1635. doi: 10.1053/j.jvca.2020.02.038. Epub 2020 Feb 29. PubMed 32276758 ↗
  • Benson MJ, Silverton N, Morrissey C, Zimmerman J. Strain Imaging: An Everyday Tool for the Perioperative Echocardiographer. J Cardiothorac Vasc Anesth. 2020 Oct;34(10):2707-2717. doi: 10.1053/j.jvca.2019.11.035. Epub 2019 Dec 7. PubMed 31919005 ↗
  • Sonny A, Alfirevic A, Sale S, Zimmerman NM, You J, Gillinov AM, Sessler DI, Duncan AE. Reduced Left Ventricular Global Longitudinal Strain Predicts Prolonged Hospitalization: A Cohort Analysis of Patients Having Aortic Valve Replacement Surgery. Anesth Analg. 2018 May;126(5):1484-1493. doi: 10.1213/ANE.0000000000002684. PubMed 29200066 ↗
  • Chan PG, Seese L, Aranda-Michel E, Sultan I, Gleason TG, Wang Y, Thoma F, Kilic A. Operative mortality in adult cardiac surgery: is the currently utilized definition justified? J Thorac Dis. 2021 Oct;13(10):5582-5591. doi: 10.21037/jtd-20-2213. PubMed 34795909 ↗
  • Denault AY, Tardif JC, Mazer CD, Lambert J; BART Investigators. Difficult and complex separation from cardiopulmonary bypass in high-risk cardiac surgical patients: a multicenter study. J Cardiothorac Vasc Anesth. 2012 Aug;26(4):608-16. doi: 10.1053/j.jvca.2012.03.031. Epub 2012 May 11. PubMed 22578975 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Jul 2026, 5 months later.

Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 5 months is below that.

Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Feb 5, 2026
StartEst.
Feb 5, 2026
Primary completionEst.
Jul 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07390903
Lead sponsor
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Collaborators
University of Rome Tor Vergata, San Raffaele University Hospital, Italy
Responsible party
mustafa emre gürcü (Attending Medical Doctor, Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital) — Principal investigator
First posted
Feb 5, 2026
Start date
Feb 5, 2026 (estimated)
Primary completion
Jul 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Feb 5, 2026

Study contacts

Mustafa E Gurcu, MD
Contact
emregurcu@gmail.com
+905058917800

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion